Shattuck Labs, Inc. Stock News

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.49 per share a year ago.

Positive results were released from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line higher-risk myelodysplastic syndrome and TP53 mu

Shattuck Labs (NASDAQ: STTK ) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of S

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Conor Richardson – Vice President-Investor Relations Taylor Schreiber – Scienti

AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose �

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.58 per share a year ago.

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.

Shattuck Labs, Inc. (NASDAQ:STTK ) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Exe

AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreib

AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr

AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot